AI assistant
Anteris Technologies Global Corp. — Board/Management Information 2016
May 26, 2016
33869_rns_2016-05-26_40712b29-c7d5-4e79-b5ed-6f9065529956.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [226 x 82] intentionally omitted <==
Admedus Ltd ABN 35 088 221 078
REGISTERED OFFICE: 26 Harris Road MalagaWestern Australia6090
COMPANY ANNOUNCEMENT
PO Box 6879 East PerthWestern Australia 6892 T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E [email protected]
ADMEDUS APPOINTS NEW BOARD DIRECTOR
-
Mr Mathew Ratty will join the Board
-
Appointment adds experience from domestic and international capital markets
Brisbane, Australia 27[th] of May 2016
Admedus today announced the appointment of Mr Mathew Ratty to its Board of Directors as a Non-Executive Director. “We welcome Mr Ratty to the Board and look forward to his insight and experience,” said Mr Wayne Paterson, Chairman of Admedus.
“Mr Ratty brings to the Board significant experience in both domestic and international capital markets as well as investment and funding feasibility analysis. These skills will benefit Admedus as we continue our growth in our global markets”, said Mr Paterson.
Mr Ratty is the co-founder of MC Management Group Pty Ltd - a long only venture capital firm operating in both the debt and equity space domestically and internationally. MC Management Group Pty Ltd is Admedus’ second largest shareholder and is primarily focused on healthcare, financials and technology equities. Mr Ratty is also a director of Gladstone Bridge Pty Ltd, a property investment and development firm.
Mr Ratty holds a First Class Honours degree in Finance from Curtin University as well as a Bachelor of Commerce degree specialising in property and corporate finance.
The Board welcomes Mr Ratty to Admedus and looks forward to his contribution to the Company’s next stage of development.
Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com Blog: www.admedus.com/au/category/news/
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100
Media :
Shevaun Cooper | PR Manager | Admedus Limited Tel: +61 (0) 417 985 599 | Email: [email protected]
==> picture [595 x 44] intentionally omitted <==
==> picture [170 x 63] intentionally omitted <==
Media Europe FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 [email protected]
US Investor
Rx Communications Group, LLC Melody A. Carey +1 917 322 2571 [email protected]
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com